Literature DB >> 17565749

Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia.

Eva D Rossmann1, Rodica Lenkei, Jeanette Lundin, Håkan Mellstedt, Anders Osterborg.   

Abstract

BACKGROUND: The fluorescence intensities of CD3, CD4 on T cells and CD20, CD22 molecules on B cells were quantitatively measured on lymphocytes from chronic lymphocytic leukemia (CLL) patients and healthy donors.
METHODS: The performance of three different types of microbeads was compared, i.e. Quantum molecules of equivalent soluble fluorochrome (Q-MESF), Quantum simply cellular (QSC), and QuantiBRITE (QB). As all PE-conjugates had a F/P ratio of 1:1, the MESF units represented also the antibody binding capacity (ABC).
RESULTS: The ABCs of CD4 and CD20 antigens estimated with QSC (ABC(QSC)) were higher than those assigned with QB (ABC(QB)) with an average difference 49%. Higher numbers of antigenic sites were obtained with Q-MESF than with QSC for CD20 antigen. On the contrary, CD4 antigenic sites numbers estimated with QSC were higher than those estimated with Q-MESF. ABC values estimated with Quantum MESF PE (ABC(Q-MESF)) were approximately 15% higher than ABC(QSC), whereas ABC(Q-MESF) was approximately 49% higher than ABC(QB). Statistically significant correlations were found between the values obtained using various standards. The present study is the first to report down-regulation of CD3 antigen on T cells from patients with CLL.
CONCLUSIONS: This study emphasizes the relevance of quantitative measurement of fluorescence intensity by flow cytometry as a standardized approach to measure and interpret the expression of some CLL markers and reduce variability of results obtained at different sites in multi-center clinical studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565749     DOI: 10.1002/cyto.b.20359

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  11 in total

1.  Variables affecting the quantitation of CD22 in neoplastic B cells.

Authors:  Gregory A Jasper; Indu Arun; David Venzon; Robert J Kreitman; Alan S Wayne; Constance M Yuan; Gerald E Marti; Maryalice Stetler-Stevenson
Journal:  Cytometry B Clin Cytom       Date:  2010-09-24       Impact factor: 3.058

2.  Quantitation of Lan antigen in Lan+, Lan+(w) and Lan- phenotypes.

Authors:  Rhiannon S McBean; Brett Wilson; Yew-Wah Liew; Catherine A Hyland; Robert L Flower
Journal:  Blood Transfus       Date:  2015-02-26       Impact factor: 3.443

3.  Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.

Authors:  Nisar A Baig; Ronald P Taylor; Margaret A Lindorfer; Amy K Church; Betsy R Laplant; Emily S Pavey; Grzegorz S Nowakowski; Clive S Zent
Journal:  Leuk Lymphoma       Date:  2012-05-21

4.  Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.

Authors:  Nisar A Baig; Ronald P Taylor; Margaret A Lindorfer; Amy K Church; Betsy R LaPlant; Adam M Pettinger; Tait D Shanafelt; Grzegorz S Nowakowski; Clive S Zent
Journal:  J Immunol       Date:  2014-01-15       Impact factor: 5.422

5.  Optimized flow cytometry protocol for analysis of surface expression of interleukin-1 receptor types I and II.

Authors:  Filipp Filippovich Vasilyev; Julia Anatolievna Lopatnikova; Sergey Vitalievich Sennikov
Journal:  Cytotechnology       Date:  2013-02-26       Impact factor: 2.058

6.  Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.

Authors:  Martin J S Dyer
Journal:  Ther Adv Hematol       Date:  2012-08

7.  Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.

Authors:  Nathalie A Johnson; Merrill Boyle; Ali Bashashati; Stephen Leach; Angela Brooks-Wilson; Laurie H Sehn; Mukesh Chhanabhai; Ryan R Brinkman; Joseph M Connors; Andrew P Weng; Randy D Gascoyne
Journal:  Blood       Date:  2008-11-24       Impact factor: 22.113

8.  Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.

Authors:  Prashant R Tembhare; Gerald Marti; Adrian Wiestner; Heba Degheidy; Mohammed Farooqui; Robert J Kreitman; Gregory A Jasper; Constance M Yuan; David Liewehr; David Venzon; Maryalice Stetler-Stevenson
Journal:  Am J Clin Pathol       Date:  2013-12       Impact factor: 2.493

9.  Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.

Authors:  Stephen W Jarantow; Barbara S Bushey; Jose R Pardinas; Ken Boakye; Eilyn R Lacy; Renouard Sanders; Manuel A Sepulveda; Sheri L Moores; Mark L Chiu
Journal:  J Biol Chem       Date:  2015-08-10       Impact factor: 5.157

10.  Flow Cytometry as a Tool for Quality Control of Fluorescent Conjugates Used in Immunoassays.

Authors:  Marta de Almeida Santiago; Bruna de Paula Fonseca E Fonseca; Christiane de Fátima da Silva Marques; Edimilson Domingos da Silva; Alvaro Luiz Bertho; Ana Cristina Martins de Almeida Nogueira
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.